PRTC
MCID: PRT010
MIFTS: 68

Parathyroid Carcinoma (PRTC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Parathyroid Carcinoma

MalaCards integrated aliases for Parathyroid Carcinoma:

Name: Parathyroid Carcinoma 57 12 20 43 58 72 36 29 13 54 6 15
Parathyroid Neoplasms 43 54 44 70
Parathyroid Cancer 73 20 43 54
Malignant Tumor of Parathyroid Gland 12 43 70
Malignant Neoplasm of Parathyroid Gland 12 43
Parathyroid Gland Adenocarcinoma 12 70
Carcinoma of Parathyroid Gland 12 43
Parathyroid Gland Carcinoma 43 17
Parathyroid Gland Cancer 12 43
Parathyroid Neoplasm 12 73
Prtc 57 72
Malignant Neoplasm of the Parathyroid 12
Malignant Parathyroid Gland Neoplasm 43
Malignant Neoplasm of Parathyroid 43
Malignant Parathyroid Gland Tumor 43
Neoplasm of the Parathyroid Gland 6
Cancer of the Parathyroid Gland 43
Malignant Parathyroid Neoplasm 43
Malignant Tumor of Parathyroid 43
Neoplasm of Parathyroid Gland 12
Malignant Parathyroid Tumor 43
Parathyroid Gland Neoplasm 12
Parathyroid Adenocarcinoma 43
Cancer of the Parathyroid 43
Carcinoma, Parathyroid 39

Characteristics:

Orphanet epidemiological data:

58
parathyroid carcinoma
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adult; Age of death: adult,elderly;

HPO:

31
parathyroid carcinoma:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:

Orphanet: 58  
Rare endocrine diseases


Summaries for Parathyroid Carcinoma

MedlinePlus Genetics : 43 Parathyroid cancer is a rare cancer that usually affects people in their forties or fifties and occurs in one of the four parathyroid glands. The parathyroid glands are located in the neck and secrete parathyroid hormone, which enhances the release of calcium into the blood.In about 90 percent of cases, the early signs of parathyroid cancer are high levels of parathyroid hormone (hyperparathyroidism) and calcium (hypercalcemia) in the blood. In these cases, the cancer is described as hormonally functional because the parathyroid glands are producing excess hormone.Many individuals with hormonally functional parathyroid cancer develop hypercalcemic crisis, in which calcium levels in the blood are very high. Neurological problems can develop, including changes in mood and depression. About 30 percent of individuals with hypercalcemia due to parathyroid cancer develop kidney and skeletal problems. These problems include increased urine production (polyuria), deposits of calcium in the kidneys (nephrocalcinosis) leading to the formation of kidney stones (nephrolithiasis), bone pain, bone loss, and increased bone fractures. Abdominal pain, inflammation of the pancreas (pancreatitis), sores (ulcers) in the lining of the digestive tract, nausea, vomiting, weight loss, and fatigue are also common.About 10 percent of cases of parathyroid cancer are described as hormonally nonfunctional. In these cases, levels of parathyroid hormone and calcium are normal. The signs and symptoms of hormonally nonfunctional parathyroid cancer are related to the tumor obstructing nearby structures in the neck. These problems include difficulty swallowing (dysphagia) and speaking (dysarthria), a hoarse voice, shortness of breath (dyspnea), or vocal cord paralysis.Up to 85 percent of individuals with parathyroid survive at least 5 years after they are diagnosed. The disease recurs in approximately half of individuals. If cancer does recur, it will commonly be within 3 years of the original diagnosis and up to 78 percent of people with recurrent cancer survive at least 5 years. Hormonally nonfunctional parathyroid cancer has a lower survival rate because it is often found at a later stage, as it does not have early signs such as increased calcium and parathyroid hormone levels.In hormonally functional parathyroid cancer, death is usually caused by organ failure (usually kidney failure) due to prolonged hypercalcemia and not directly due to the tumor. In hormonally nonfunctional parathyroid cancer, the cause of death is typically related to the tumor itself, such as its impact on the function of nearby structures or its spread to other tissues (metastasis).

MalaCards based summary : Parathyroid Carcinoma, also known as parathyroid neoplasms, is related to hyperparathyroidism 1 and osteitis fibrosa. An important gene associated with Parathyroid Carcinoma is CDC73 (Cell Division Cycle 73), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Aldosterone synthesis and secretion. The drugs Cinacalcet and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include parathyroid glands located in the neck, thyroid and bone, and related phenotypes are parathyroid carcinoma and primary hyperparathyroidism

Disease Ontology : 12 An endocrine gland cancer located in the parathyroid glands located in the neck.

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 143 Definition Parathyroid carcinoma (PRTC) is a very rare, slow-growing, clinically serious endocrine tumor that generally develops in mid-adulthood. PRTC presents as a palpable painless mass in the neck and causes severe hypercalcemia and related symptoms, non-specific gastrointestinal manifestations, as well as renal and bone complications related to primary hyperparathyroidism (nephrolithiasis, impaired renal function, osteoporosis, bone pain, and pathologic fractures, etc.). Some PRTCs are however non-functioning tumors.

KEGG : 36 Parathyroid carcinoma (PC) is a highly aggressive endocrine tumor, with an annual incidence of less than 1 per million. Over 90% of patients present with excess parathyroid hormone (PTH), representing <1-5% of all patients with primary hyperparathyroidism. PC is associated with mutations in the HRPT2/CDC73 gene and with decreased parafibromin and calcium-sensing receptor (CASR) expression. Negative parafibromin staining together with a CDC73 gene mutation increases the likelihood of malignancy and also predicts the clinical outcome, namely local invasion and/or metastases and mortality. An increased mortality is predicted by either of these abnormality combined with down regulation of the calcium-sensing receptor (CaSR) expression.

UniProtKB/Swiss-Prot : 72 Parathyroid carcinoma: These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.

Wikipedia : 73 Parathyroid carcinoma is a rare cancer resulting in parathyroid adenoma to carcinoma progression. It... more...

More information from OMIM: 608266

Related Diseases for Parathyroid Carcinoma

Diseases related to Parathyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 256)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 1 32.1 MEN1 CDC73
2 osteitis fibrosa 31.8 PTH CDC73 CASR CALCA
3 hyperparathyroidism 2 with jaw tumors 31.6 RET MEN1 CDC73 CCND1 CASR
4 hyperparathyroidism 31.1 RET PTH MEN1 CDC73 CASR CALCA
5 secondary hyperparathyroidism 30.8 PTH MEN1 CASR CALCA
6 thyroid carcinoma 30.8 RET LGALS3 CALCA
7 primary hyperparathyroidism 30.8 RET PTH MEN1 CDC73 CCND1 CASR
8 multiple endocrine neoplasia 30.5 RET PTH MEN1 CDC73 CALCA
9 goiter 30.4 RET LGALS3 CALCA
10 bone resorption disease 30.4 PTH CTNNB1 CALCA
11 multiple endocrine neoplasia, type i 30.3 RET PTH MEN1 CDC73 CASR
12 hypercalcemia, infantile, 1 30.3 PTH CASR CALCA
13 thyroid carcinoma, familial medullary 30.2 RET MEN1 CALCA
14 papillary carcinoma 30.2 RET LGALS3 CALCA
15 substernal goiter 30.2 PTH CALCA
16 thyroid gland medullary carcinoma 30.1 RET PTH MEN1 CALCA
17 nodular goiter 30.0 RET LGALS3 CALCA
18 hypoparathyroidism 29.9 RET PTH CASR CALCA
19 uremia 29.9 PTH MEN1 CASR
20 parathyroid adenoma 29.8 RET PTH MEN1 LGALS3 CTNNB1 CDC73
21 islet cell tumor 29.8 RET MEN1 CALCA
22 papillary thyroid microcarcinoma 29.7 MKI67 CALCA
23 familial adenomatous polyposis 29.7 CTNNB1 CCND1 APC
24 pheochromocytoma 29.5 TERT RET MEN1 CCND1 CALCA
25 neuroendocrine tumor 29.3 RET MKI67 MEN1 CALCA
26 multiple endocrine neoplasia, type iia 29.2 RET PTH MEN1 CDC73 CASR CALCA
27 adenoma 29.2 RET PTH MKI67 MEN1 LGALS3 CTNNB1
28 adenocarcinoma 29.1 RET RB1 CTNNB1 CCND1 APC
29 meningioma, familial 29.1 TERT RET MKI67 MEN1
30 thyroid gland follicular carcinoma 29.1 TERT RET LGALS3 CTNNB1 CCND1 CALCA
31 lung cancer susceptibility 3 29.0 TERT RB1 CTNNB1 CCND1 APC
32 lynch syndrome 28.9 TERT RB1 CTNNB1 CCND1 APC
33 thyroid gland anaplastic carcinoma 28.8 TERT RET LGALS3 CTNNB1 CCND1 CALCA
34 parathyroid gland disease 28.6 RET PTH MIR30B MEN1 CDC73 CASR
35 thyroid gland cancer 28.4 TERT RET PTH MEN1 LGALS3 CTNNB1
36 bone disease 10.4
37 parathyroid transitional clear cell adenoma 10.4 PTH MEN1
38 malignant ovarian brenner tumor 10.4 PTH CALCA
39 kidney disease 10.3
40 endocrine pancreas disease 10.3 MEN1 CALCA
41 rare tumor 10.3
42 isthmus cancer 10.3 LGALS3 CALCA
43 pancreatic cholera 10.3 MEN1 CALCA
44 gorham's disease 10.3 PTH CALCA
45 carcinoid syndrome 10.3 MEN1 CALCA
46 hypervitaminosis d 10.3 PTH CALCA
47 cerebellar angioblastoma 10.3 MEN1 CALCA
48 cecal benign neoplasm 10.3 TERT MEN1
49 cecum adenoma 10.3 TERT MEN1
50 thyroid sarcoma 10.3 TERT CALCA

Comorbidity relations with Parathyroid Carcinoma via Phenotypic Disease Network (PDN):


Hyperparathyroidism

Graphical network of the top 20 diseases related to Parathyroid Carcinoma:



Diseases related to Parathyroid Carcinoma

Symptoms & Phenotypes for Parathyroid Carcinoma

Human phenotypes related to Parathyroid Carcinoma:

58 31 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 parathyroid carcinoma 58 31 obligate (100%) Obligate (100%) HP:0006780
2 primary hyperparathyroidism 58 31 obligate (100%) Obligate (100%) HP:0008200
3 hypophosphatemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002148
4 hypercalciuria 58 31 hallmark (90%) Very frequent (99-80%) HP:0002150
5 elevated circulating parathyroid hormone level 58 31 hallmark (90%) Very frequent (99-80%) HP:0003165
6 dysphagia 58 31 frequent (33%) Frequent (79-30%) HP:0002015
7 polydipsia 58 31 frequent (33%) Frequent (79-30%) HP:0001959
8 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
9 osteoporosis 58 31 frequent (33%) Frequent (79-30%) HP:0000939
10 fibroma 58 31 frequent (33%) Frequent (79-30%) HP:0010614
11 nephrocalcinosis 58 31 frequent (33%) Frequent (79-30%) HP:0000121
12 nephrolithiasis 58 31 frequent (33%) Frequent (79-30%) HP:0000787
13 hoarse voice 58 31 frequent (33%) Frequent (79-30%) HP:0001609
14 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
15 uterine leiomyoma 58 31 frequent (33%) Frequent (79-30%) HP:0000131
16 infantile hypercalcemia 58 31 frequent (33%) Frequent (79-30%) HP:0008250
17 shortened qt interval 58 31 frequent (33%) Frequent (79-30%) HP:0012232
18 nausea and vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002017
19 constipation 58 31 occasional (7.5%) Occasional (29-5%) HP:0002019
20 muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0001324
21 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
22 peptic ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0004398
23 headache 58 31 occasional (7.5%) Occasional (29-5%) HP:0002315
24 bone pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002653
25 chondrocalcinosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000934
26 renal cyst 58 31 occasional (7.5%) Occasional (29-5%) HP:0000107
27 pancreatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001733
28 episodic abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002574
29 renal hamartoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0008696
30 mandibular pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0200025
31 pancreatic adenocarcinoma 58 31 very rare (1%) Very rare (<4-1%) HP:0006725
32 lipoma 58 31 very rare (1%) Very rare (<4-1%) HP:0012032
33 nephroblastoma 58 31 very rare (1%) Very rare (<4-1%) HP:0002667
34 thyroid carcinoma 58 31 very rare (1%) Very rare (<4-1%) HP:0002890
35 testicular neoplasm 58 31 very rare (1%) Very rare (<4-1%) HP:0010788
36 hypercalcemia 58 31 Obligate (100%) HP:0003072
37 hyperparathyroidism 31 HP:0000843
38 abnormality of the parathyroid morphology 58 Very frequent (99-80%)

Clinical features from OMIM®:

608266 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-111 9.64 MEN1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.64 MEN1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.64 APC
4 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.64 CCND1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.64 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.64 MEN1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.64 RB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.64 RB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.64 RB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.64 APC
11 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.64 APC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.64 CCND1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.64 CCND1 RB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.64 CCND1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.64 CCND1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.64 RB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.64 CTNNB1 MEN1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.64 RB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-98 9.64 MEN1

MGI Mouse Phenotypes related to Parathyroid Carcinoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 APC CASR CCND1 CDC73 CTNNB1 LGALS3
2 growth/size/body region MP:0005378 10.37 APC CASR CCND1 CDC73 CTNNB1 LGALS3
3 cardiovascular system MP:0005385 10.34 APC CCND1 CDC73 CTNNB1 LGALS3 MEN1
4 immune system MP:0005387 10.34 APC CASR CCND1 CDC73 CTNNB1 LGALS3
5 hematopoietic system MP:0005397 10.33 APC CASR CCND1 CDC73 CTNNB1 LGALS3
6 digestive/alimentary MP:0005381 10.32 APC CASR CCND1 CDC73 CTNNB1 LGALS3
7 endocrine/exocrine gland MP:0005379 10.31 APC CASR CCND1 CDC73 CTNNB1 MEN1
8 homeostasis/metabolism MP:0005376 10.31 APC CASR CCND1 CDC73 CTNNB1 LGALS3
9 mortality/aging MP:0010768 10.27 APC CASR CCND1 CDC73 CTNNB1 LGALS3
10 craniofacial MP:0005382 10.19 APC CASR CCND1 CDC73 CTNNB1 MEN1
11 liver/biliary system MP:0005370 10.13 APC CDC73 CTNNB1 LGALS3 MEN1 RB1
12 integument MP:0010771 10.11 APC CASR CCND1 CDC73 CTNNB1 LGALS3
13 nervous system MP:0003631 10.11 APC CASR CCND1 CDC73 CTNNB1 LGALS3
14 neoplasm MP:0002006 10.1 APC CCND1 CDC73 CTNNB1 LGALS3 MEN1
15 muscle MP:0005369 9.98 APC CASR CDC73 CTNNB1 MEN1 RB1
16 limbs/digits/tail MP:0005371 9.97 APC CTNNB1 PTH RB1 RET UCHL1
17 normal MP:0002873 9.92 APC CCND1 CTNNB1 MKI67 RB1 RET
18 renal/urinary system MP:0005367 9.91 APC CASR CDC73 CTNNB1 LGALS3 RB1
19 reproductive system MP:0005389 9.81 APC CCND1 CDC73 CTNNB1 LGALS3 MEN1
20 respiratory system MP:0005388 9.56 CCND1 CDC73 CTNNB1 LGALS3 RB1 RET
21 skeleton MP:0005390 9.32 APC CASR CCND1 CDC73 CTNNB1 LGALS3

Drugs & Therapeutics for Parathyroid Carcinoma

Drugs for Parathyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cinacalcet Approved Phase 4 226256-56-0 156419
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
6
Codeine Approved, Illicit Phase 4 76-57-3 5284371
7 Hormone Antagonists Phase 4
8 Hormones Phase 4
9 Calcium, Dietary Phase 4
10 Pharmaceutical Solutions Phase 4
11 Respiratory System Agents Phase 4
12 Analgesics, Opioid Phase 4
13 Narcotics Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Analgesics Phase 4
16 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
17 Antitussive Agents Phase 4
18 Antipyretics Phase 4
19
Calcium Nutraceutical Phase 4 7440-70-2 271
20
Denosumab Approved Phase 3 615258-40-7
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
22
Choline Approved, Nutraceutical Phase 3 62-49-7 305
23 Vitamins Phase 3
24 Calciferol Phase 3
25 Gastrointestinal Agents Phase 3
26 Antimetabolites Phase 3
27 Nootropic Agents Phase 3
28 Lipid Regulating Agents Phase 3
29 Technetium Tc 99m Sestamibi Phase 3
30 Hypolipidemic Agents Phase 3
31 Diphosphonates Phase 2
32
Paclitaxel Approved, Vet_approved Phase 1 33069-62-4 36314
33
Trastuzumab Approved, Investigational Phase 1 180288-69-1 9903
34
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
35
Dacarbazine Approved, Investigational Phase 1 4342-03-4 5351166 2942
36
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
37 Antineoplastic Agents, Immunological Phase 1
38 Albumin-Bound Paclitaxel Phase 1
39 Angiogenesis Inhibitors Phase 1
40 Adjuvants, Immunologic Phase 1
41 Interleukin-12 Phase 1
42 Immunologic Factors Phase 1
43 Alkylating Agents Phase 1
44
Gefitinib Approved, Investigational 184475-35-2 123631
45
Parathyroid hormone Approved, Investigational 9002-64-6
46
Lidocaine Approved, Vet_approved Early Phase 1 137-58-6 3676
47
Epinephrine Approved, Vet_approved Early Phase 1 51-43-4 5816
48
Racepinephrine Approved Early Phase 1 329-65-7 838
49
Bupivacaine Approved, Investigational Early Phase 1 2180-92-9, 38396-39-3 2474
50 Protein Kinase Inhibitors

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism. Completed NCT00037518 Phase 4 AMG 073
2 Intravenous Or Topical Lidocaine And Neuromonitoring in Thyroid Surgery (IOLANT Study) Recruiting NCT04574947 Phase 4 Intravenous lidocaine;Intravenous placebo
3 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Active, not recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
4 An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Completed NCT01460030 Phase 3 Cinacalcet HCl
5 An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy Completed NCT03280264 Phase 3 KHK7580
6 Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Completed NCT03027557 Phase 3 Cinacalcet 30 mg Tablet;Denosumab Inj 60 mg/ml
7 18F-Fluorocholine for the Detection of Parathyroid Adenomas Recruiting NCT03764007 Phase 2, Phase 3 Fluorocholine PET
8 Phase III Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention Recruiting NCT04040946 Phase 3
9 Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas Completed NCT02432599 Phase 2
10 A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates Completed NCT00896454 Phase 2 denosumab
11 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Withdrawn NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
12 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
13 Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Completed NCT00580320 Phase 1 Dacarbazine and bortezomib
14 Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid Unknown status NCT03516747
15 Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study Unknown status NCT02843542
16 Evaluation of a New CZT System for Imaging in Routine Nuclear Medicine Examination Unknown status NCT01084356
17 Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease Unknown status NCT01647503
18 Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior Completed NCT03046524
19 Use of Hypocalcemic Intraarterial Infusion Into the Thyroid/Parathyroid Bed to Localize Occult Parathyroid Adenomas Completed NCT00001394
20 Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer? Completed NCT01776385
21 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
22 Studies of Hyperparathyroidism and Related Disorders Completed NCT00001277 68Ga-Dotatate;18F-DOPA
23 Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU)Treatment Procedure: A Monocentre, Open, Uncontrolled Study Completed NCT01060982
24 Amino Acid Transport Imaging of Parathyroid Adenomas With Anti-3-[18F]FACBC Completed NCT01574287 FACBC
25 The Utility of 18F-fluorocholine PET/CT in the Imaging of Parathyroid Adenomas Completed NCT04570033
26 Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents Recruiting NCT03039439
27 Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms Recruiting NCT01005654
28 Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery Using Quantitative Analysis of Scintigraphy Results on Hybrid SPECT-CT Imaging Recruiting NCT04344886
29 Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy Recruiting NCT04299425
30 Intraoperative Injection of Exparel Effect on Postoperative Opioid Use in Thyroid and Parathyroid Surgery Not yet recruiting NCT04085913 Early Phase 1 Lidocaine Epinephrine;Bupivacaine Hydrochloride-EPINEPHrine;Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine
31 The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Not yet recruiting NCT04028479 Systemic Treatment (T)
32 Cohort Trial on Perioperative Localization Techniques of Parathyroid Adenomas Not yet recruiting NCT04013100
33 Localization of Parathyroid Adenomas Using MRI and SPECT Fusion Software in Patients With Persistent or Recurrent Hyperparathyroidism Terminated NCT00639405
34 High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma Terminated NCT01291498
35 Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism Withdrawn NCT02381925

Search NIH Clinical Center for Parathyroid Carcinoma

Cochrane evidence based reviews: parathyroid neoplasms

Genetic Tests for Parathyroid Carcinoma

Genetic tests related to Parathyroid Carcinoma:

# Genetic test Affiliating Genes
1 Parathyroid Carcinoma 29 CDC73

Anatomical Context for Parathyroid Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Parathyroid Carcinoma:

19
Parathyroid Glands Located In The Neck

MalaCards organs/tissues related to Parathyroid Carcinoma:

40
Thyroid, Bone, Kidney, Pancreas, Pituitary, Breast, Lymph Node

Publications for Parathyroid Carcinoma

Articles related to Parathyroid Carcinoma:

(show top 50) (show all 1294)
# Title Authors PMID Year
1
Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. 54 61 6 57
14585940 2003
2
Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. 54 6 61
19017757 2009
3
Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. 6 54 61
16720667 2006
4
Large deletion at the CDC73 gene locus and search for predictive markers of the presence of a CDC73 genetic lesion. 6 61
29755684 2018
5
CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism. 61 6
29040582 2017
6
Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family. 61 6
28774260 2017
7
Hyperparathyroidism-jaw tumor syndrome: Results of operative management. 61 6
25444225 2014
8
CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma. 6 61
24823466 2014
9
Recurrent hyperparathyroidism and a novel nonsense mutation in a patient with hyperparathyriodism-jaw tumor syndrome. 61 6
23757631 2013
10
Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. 61 6
23293331 2013
11
Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. 6 61
23029104 2012
12
Novel nonsense CDC73 mutations in Chinese patients with parathyroid tumors. 6 61
21732217 2011
13
[Clinical and molecular genetic analyses for a sporadic parathyroid carcinoma]. 6 61
20979880 2010
14
Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. 6 54
20052758 2010
15
The effect of disease-associated HRPT2 mutations on splicing. 6 61
19332451 2009
16
Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. 6 54
17314275 2007
17
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. 6 54
15531515 2004
18
Clinical review 122: Parathyroid carcinoma. 57 61
11157996 2001
19
Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. 61 57
3985291 1985
20
Early-onset, severe, and recurrent primary hyperparathyroidism associated with a novel CDC73 mutation. 6
25959515 2015
21
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
22
Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese. 6
24716902 2014
23
Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. 6
22187299 2012
24
Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses. 6
21360064 2011
25
Utilisation of a cryptic non-canonical donor splice site of the gene encoding PARAFIBROMIN is associated with familial isolated primary hyperparathyroidism. 6
16061557 2005
26
A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. 6
15613436 2005
27
Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). 6
14985403 2004
28
Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. 6
14715834 2004
29
HRPT2, a marker of parathyroid cancer. 57
14585935 2003
30
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. 6
12434154 2002
31
Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. 54 61
19926710 2010
32
The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. 54 61
19906718 2010
33
Molecular genetics of parathyroid disease. 61 54
19373510 2009
34
Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation. 61 54
19491073 2009
35
Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. 61 54
19148484 2009
36
Defining a molecular phenotype for benign and malignant parathyroid tumors. 61 54
19107770 2009
37
Primary hyperparathyroidism: a current perspective. 54 61
18684024 2008
38
Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. 54 61
18436011 2008
39
Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. 54 61
18338208 2008
40
Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. 61 54
18217513 2007
41
Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. 54 61
17555500 2007
42
Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? 61 54
17468190 2007
43
Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. 54 61
16931959 2006
44
Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome. 54 61
16817812 2006
45
Parathyroid carcinoma. 54 61
16357559 2006
46
Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. 54 61
16116486 2005
47
Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. 54 61
16112008 2005
48
Parathyroid carcinoma. 61 54
15719375 2005
49
Parathyroid carcinoma: an overview. 54 61
15731573 2005
50
Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. 54 61
15475453 2004

Variations for Parathyroid Carcinoma

ClinVar genetic disease variations for Parathyroid Carcinoma:

6 (show top 50) (show all 475)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CDC73 NM_024529.4(CDC73):c.128G>A (p.Trp43Ter) SNV Pathogenic 3271 rs121434263 GRCh37: 1:193091458-193091458
GRCh38: 1:193122328-193122328
2 CDC73 NM_024529.4(CDC73):c.85del (p.Glu29fs) Deletion Pathogenic 3280 rs587776560 GRCh37: 1:193091412-193091412
GRCh38: 1:193122282-193122282
3 CDC73 NM_024529.4(CDC73):c.13_30del (p.Leu5_Gln10del) Deletion Pathogenic 3281 rs587776561 GRCh37: 1:193091342-193091359
GRCh38: 1:193122212-193122229
4 CDC73 NM_024529.4(CDC73):c.766_767del (p.Val256fs) Deletion Pathogenic 21687 rs80356650 GRCh37: 1:193117032-193117033
GRCh38: 1:193147902-193147903
5 CDC73 NM_024529.4(CDC73):c.245del (p.Asn82fs) Deletion Pathogenic 403878 rs1060500009 GRCh37: 1:193099308-193099308
GRCh38: 1:193130178-193130178
6 CDC73 NM_024529.4(CDC73):c.4del (p.Ala2fs) Deletion Pathogenic 403893 rs1060500020 GRCh37: 1:193091333-193091333
GRCh38: 1:193122203-193122203
7 CDC73 NM_024529.4(CDC73):c.237+1G>C SNV Pathogenic 403882 rs794727303 GRCh37: 1:193094348-193094348
GRCh38: 1:193125218-193125218
8 CDC73 NM_024529.4(CDC73):c.505C>T (p.Gln169Ter) SNV Pathogenic 462764 rs1553279088 GRCh37: 1:193107296-193107296
GRCh38: 1:193138166-193138166
9 CDC73 NM_024529.5(CDC73):c.1001_1004del (p.Thr334fs) Deletion Pathogenic 844763 GRCh37: 1:193172953-193172956
GRCh38: 1:193203823-193203826
10 CDC73 and overlap with 1 gene(s) NC_000001.11:g.(?_193122201)_(193250712_?)del Deletion Pathogenic 830490 GRCh37: 1:193091331-193219842
GRCh38:
11 CDC73 NC_000001.11:g.(?_193122191)_(193150392_?)del Deletion Pathogenic 830553 GRCh37: 1:193091321-193119522
GRCh38:
12 CDC73 NC_000001.11:g.(?_193122201)_(193125227_?)del Deletion Pathogenic 830741 GRCh37: 1:193091331-193094357
GRCh38:
13 CDC73 NC_000001.11:g.(?_193125102)_(193130253_?)del Deletion Pathogenic 831107 GRCh37: 1:193094232-193099383
GRCh38:
14 CDC73 NC_000001.11:g.(?_193122191)_(193125227_?)del Deletion Pathogenic 831275 GRCh37: 1:193091321-193094357
GRCh38:
15 CDC73 NC_000001.11:g.(?_193122191)_(193152454_?)del Deletion Pathogenic 832317 GRCh37: 1:193091321-193121584
GRCh38:
16 CDC73 NC_000001.11:g.(?_193135381)_(193138183_?)del Deletion Pathogenic 833443 GRCh37: 1:193104511-193107313
GRCh38:
17 CDC73 NM_024529.4(CDC73):c.358C>T (p.Arg120Ter) SNV Pathogenic 642112 rs1572150469 GRCh37: 1:193104571-193104571
GRCh38: 1:193135441-193135441
18 CDC73 NM_024529.5(CDC73):c.718del (p.Ser240fs) Deletion Pathogenic 660497 rs1572154885 GRCh37: 1:193111183-193111183
GRCh38: 1:193142053-193142053
19 CDC73 NM_024529.5(CDC73):c.1247del (p.Gly416fs) Deletion Pathogenic 658249 rs1572215344 GRCh37: 1:193202211-193202211
GRCh38: 1:193233081-193233081
20 CDC73 NM_024529.4(CDC73):c.664C>T (p.Arg222Ter) SNV Pathogenic 658835 rs770439843 GRCh37: 1:193111131-193111131
GRCh38: 1:193142001-193142001
21 CDC73 NM_024529.4(CDC73):c.376C>T (p.Arg126Ter) SNV Pathogenic 462760 rs1553278844 GRCh37: 1:193104672-193104672
GRCh38: 1:193135542-193135542
22 CDC73 NM_024529.4(CDC73):c.53_54del (p.Ile18fs) Deletion Pathogenic 567635 rs1558276157 GRCh37: 1:193091383-193091384
GRCh38: 1:193122253-193122254
23 CDC73 NM_024529.4(CDC73):c.1052del (p.Pro351fs) Deletion Pathogenic 462737 rs1553288362 GRCh37: 1:193181212-193181212
GRCh38: 1:193212082-193212082
24 CDC73 NM_024529.4(CDC73):c.375dup (p.Arg126fs) Duplication Pathogenic 3275 rs1572150584 GRCh37: 1:193104668-193104669
GRCh38: 1:193135538-193135539
25 CDC73 NM_024529.4(CDC73):c.679_680AG[3] (p.Arg229fs) Microsatellite Pathogenic 3278 rs760591174 GRCh37: 1:193111146-193111149
GRCh38: 1:193142016-193142019
26 CDC73 NM_024529.4(CDC73):c.483dup (p.Glu162fs) Duplication Pathogenic 531648 rs1553279085 GRCh37: 1:193107271-193107272
GRCh38: 1:193138141-193138142
27 CDC73 NM_024529.4(CDC73):c.12_31dup (p.Tyr11fs) Duplication Pathogenic 579524 rs1558276082 GRCh37: 1:193091339-193091340
GRCh38: 1:193122209-193122210
28 CDC73 NM_024529.5(CDC73):c.220dup (p.Tyr74fs) Duplication Pathogenic 801586 rs1572142597 GRCh37: 1:193094327-193094328
GRCh38: 1:193125197-193125198
29 CDC73 NM_024529.5(CDC73):c.1405dup (p.Ile469fs) Duplication Pathogenic 938616 GRCh37: 1:193205473-193205474
GRCh38: 1:193236343-193236344
30 CDC73 NM_024529.5(CDC73):c.7dup (p.Asp3fs) Duplication Pathogenic 939836 GRCh37: 1:193091335-193091336
GRCh38: 1:193122205-193122206
31 CDC73 NM_024529.4(CDC73):c.451_452GA[2] (p.Arg152fs) Microsatellite Pathogenic 403892 rs1060500019 GRCh37: 1:193107241-193107242
GRCh38: 1:193138111-193138112
32 CDC73 NM_024529.5(CDC73):c.64G>T (p.Gly22Ter) SNV Pathogenic 967087 GRCh37: 1:193091394-193091394
GRCh38: 1:193122264-193122264
33 CDC73 NM_024529.5(CDC73):c.157G>T (p.Glu53Ter) SNV Pathogenic 970108 GRCh37: 1:193094267-193094267
GRCh38: 1:193125137-193125137
34 CDC73 NM_024529.4(CDC73):c.162C>G (p.Tyr54Ter) SNV Pathogenic 3274 rs121434265 GRCh37: 1:193094272-193094272
GRCh38: 1:193125142-193125142
35 CDC73 NC_000001.11:g.(?_193130174)_(193130243_?)del Deletion Pathogenic 417319 GRCh37: 1:193099304-193099373
GRCh38: 1:193130174-193130243
36 CDC73 and overlap with 2 gene(s) NC_000001.11:g.(?_193122191)_(193250722_?)del Deletion Pathogenic 647462 GRCh37: 1:193091321-193219852
GRCh38: 1:193122191-193250722
37 CDC73 NC_000001.11:g.(?_193122191)_(193122341_?)del Deletion Pathogenic 583491 GRCh37: 1:193091321-193091471
GRCh38: 1:193122191-193122341
38 CDC73 NC_000001.11:g.(?_193236246)_(193236366_?)del Deletion Pathogenic 583777 GRCh37: 1:193205376-193205496
GRCh38: 1:193236246-193236366
39 CDC73 NM_024529.4(CDC73):c.679_680insAG (p.Arg227fs) Insertion Pathogenic 3270 rs80356649 GRCh37: 1:193111146-193111147
GRCh38: 1:193142016-193142017
40 CDC73 NM_024529.5(CDC73):c.271C>T (p.Arg91Ter) SNV Pathogenic 846304 GRCh37: 1:193099337-193099337
GRCh38: 1:193130207-193130207
41 CDC73 NM_024529.4(CDC73):c.131+1G>A SNV Pathogenic 3276 rs587776558 GRCh37: 1:193091462-193091462
GRCh38: 1:193122332-193122332
42 CDC73 NM_024529.4(CDC73):c.85G>T (p.Glu29Ter) SNV Pathogenic 429954 rs1131691698 GRCh37: 1:193091415-193091415
GRCh38: 1:193122285-193122285
43 CDC73 NM_024529.4(CDC73):c.226C>T (p.Arg76Ter) SNV Pathogenic 279741 rs886041158 GRCh37: 1:193094336-193094336
GRCh38: 1:193125206-193125206
44 overlap with 16 genes Deletion Pathogenic 560081 GRCh37: 1:191888324-194584888
GRCh38: 1:191919194-194615758
45 CDC73 NM_024529.5(CDC73):c.679_680AG[6] (p.Val230fs) Microsatellite Pathogenic 241496 rs760591174 GRCh37: 1:193111145-193111146
GRCh38: 1:193142015-193142016
46 CDC73 NM_024529.4(CDC73):c.478_479CA[1] (p.His160fs) Microsatellite Likely pathogenic 633148 rs1572152420 GRCh37: 1:193107269-193107270
GRCh38: 1:193138139-193138140
47 CTNNB1 NM_001904.4(CTNNB1):c.98C>G (p.Ser33Cys) SNV Likely pathogenic 376231 rs121913400 GRCh37: 3:41266101-41266101
GRCh38: 3:41224610-41224610
48 CTNNB1 NM_001904.4(CTNNB1):c.109T>G (p.Ser37Ala) SNV Likely pathogenic 376235 rs121913228 GRCh37: 3:41266112-41266112
GRCh38: 3:41224621-41224621
49 CDC73 NM_024529.4(CDC73):c.1A>G (p.Met1Val) SNV Likely pathogenic 582687 rs1558276054 GRCh37: 1:193091331-193091331
GRCh38: 1:193122201-193122201
50 CDC73 NC_000001.11:g.(?_193130168)_(193135595_?)del Deletion Likely pathogenic 462735 GRCh37: 1:193099298-193104725
GRCh38: 1:193130168-193135595

Expression for Parathyroid Carcinoma

Search GEO for disease gene expression data for Parathyroid Carcinoma.

Pathways for Parathyroid Carcinoma

Pathways related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 TERT RB1 CTNNB1 CCND1 APC
2
Show member pathways
12.68 RB1 MEN1 CTNNB1 CCND1 APC
3
Show member pathways
12.65 TERT MEN1 CTNNB1 CDC73 APC
4
Show member pathways
12.62 RET RB1 CTNNB1 CCND1 APC
5
Show member pathways
12.5 TERT RB1 CTNNB1 CCND1 APC
6 12.43 UCHL1 RET MKI67 CALCA
7 12.36 TERT RET RB1 CTNNB1 CCND1 APC
8
Show member pathways
12.34 CTNNB1 CDC73 CCND1 APC
9 12.32 RB1 MKI67 CDC73 CCND1
10 12.22 RB1 CTNNB1 CCND1 APC
11 12.12 RB1 MEN1 CCND1 APC
12 11.85 RB1 LGALS3 CCND1
13 11.82 CTNNB1 CCND1 APC
14 11.67 RB1 CTNNB1 CCND1
15 11.6 RB1 CTNNB1 CCND1 APC
16 11.3 CTNNB1 CCND1 APC
17 11.21 CTNNB1 CCND1 APC
18 11.13 MEN1 CTNNB1 APC
19 10.86 CTNNB1 APC
20 10.82 TERT CTNNB1 CCND1 APC
21 10.68 MEN1 CTNNB1
22 10.51 CTNNB1 CCND1 APC

GO Terms for Parathyroid Carcinoma

Cellular components related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.93 TET2 TERT RB1 MKI67 MEN1 LGALS3
2 bicellular tight junction GO:0005923 9.43 CTNNB1 CCND1 APC
3 beta-catenin destruction complex GO:0030877 8.96 CTNNB1 APC
4 Wnt signalosome GO:1990909 8.62 CTNNB1 APC

Biological processes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.89 TET2 RB1 MKI67 CDC73 CCND1
2 negative regulation of gene expression GO:0010629 9.78 TERT RB1 PTH CTNNB1
3 response to organic cyclic compound GO:0014070 9.75 TET2 CCND1 CASR
4 response to drug GO:0042493 9.73 RET PTH CTNNB1 CCND1
5 cellular calcium ion homeostasis GO:0006874 9.72 PTH CASR CALCA
6 Wnt signaling pathway GO:0016055 9.71 CTNNB1 CDC73 CCND1 APC
7 response to pain GO:0048265 9.57 RET CALCA
8 positive regulation of calcium ion import GO:0090280 9.56 LGALS3 CASR
9 positive regulation of macrophage differentiation GO:0045651 9.54 RB1 CALCA
10 negative regulation of epithelial cell proliferation GO:0050680 9.54 RB1 MEN1 CDC73
11 regulation of T cell proliferation GO:0042129 9.52 LGALS3 CTNNB1
12 positive regulation of transcription elongation from RNA polymerase II promoter GO:0032968 9.51 CTNNB1 CDC73
13 neuron maturation GO:0042551 9.46 RET RB1
14 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.43 RB1 CDC73 APC
15 negative regulation of cell proliferation GO:0008285 9.35 RB1 MEN1 CTNNB1 CDC73 APC
16 response to fibroblast growth factor GO:0071774 9.32 PTH CASR
17 endodermal cell fate commitment GO:0001711 9.16 CTNNB1 CDC73
18 beta-catenin-TCF complex assembly GO:1904837 8.92 TERT MEN1 CTNNB1 CDC73

Molecular functions related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 8.8 TERT PTH MEN1

Sources for Parathyroid Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....